Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like.;The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together."/>
公开/公告号US10781180B2
专利类型
公开/公告日2020-09-22
原文格式PDF
申请/专利权人 ARENA PHARMACEUTICALS INC.;
申请/专利号US201816177672
发明设计人 BRADLEY TEEGARDEN;YIFENG XIONG;SONJA STRAH-PLEYNET;HONNAPPA JAYAKUMAR;PETER I. DOSA;KONRAD FEICHTINGER;MARTIN CASPER;JUERG LEHMANN;ROBERT M. JONES;DAVID J. UNETT;JIN SUN KAROLINE CHOI;
申请日2018-11-01
分类号C07D401/12;C07D403/12;C07D231/12;C07D405/12;C07D409/12;C07D413/12;C07D487/08;C07D231/16;C07D417/12;A61K31/5377;C07D413/10;
国家 US
入库时间 2022-08-21 11:30:37